Sandra E. Geurts

Maastricht, LI, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

Treatment and survival of de novo HER2-positive metastatic breast cancer across regional cancer networks in the Netherlands: a cohort study.

Treatment and survival of de novo HER2-positive metastatic breast cancer across regional cancer networks in the Netherlands: a cohort study.

Journal: ESMO real world data and digital oncology

Published: September 05, 2026

Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study.

Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study.

Journal: Breast (Edinburgh, Scotland)

Published: March 30, 2026

The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [ 18 F] fluorodeoxyglucose PET.

The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [ 18 F] fluorodeoxyglucose PET.

Journal: Nuclear medicine communications

Published: February 26, 2026

Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study.

Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study.

Journal: Breast (Edinburgh, Scotland)

Published: July 28, 2025

Receptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry.

Receptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry.

Journal: Clinical breast cancer

Published: April 24, 2025

Response to letter: a critical appraisal of the DATA trial analysis on the prognostic and predictive value of the luminal-like subtype.

Response to letter: a critical appraisal of the DATA trial analysis on the prognostic and predictive value of the luminal-like subtype.

Journal: ESMO open

Published: April 16, 2025

A review of the association between baseline [ 18 F] fluorodeoxyglucose uptake and axillary pathological complete response in node-positive breast cancer patients: focus on clinical subtypes.

A review of the association between baseline [ 18 F] fluorodeoxyglucose uptake and axillary pathological complete response in node-positive breast cancer patients: focus on clinical subtypes.

Journal: Nuclear medicine communications

Published: April 03, 2025

Response to letter re: The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

Response to letter re: The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

Journal: ESMO open

Published: February 26, 2025

Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients.

Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 07, 2025

Population-based Cohort Study on Treatment and Overall Survival of Patients Clinically Diagnosed With T1 Ampullary Cancer.

Population-based Cohort Study on Treatment and Overall Survival of Patients Clinically Diagnosed With T1 Ampullary Cancer.

Journal: Annals of surgery

Published: October 29, 2024

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

Journal: ESMO open

Published: October 12, 2024

Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial.

Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial.

Journal: Breast cancer research and treatment

Published: May 05, 2024

Showing 1-12 of 63

Last Updated: 09/26/2026